Padcev 30 mg powder for concentrate for solution for infusion, PF-08634404 clinical trials

C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.

This study is testing a new medicine, PF-08634404, on its own or with an existing drug, Enfortumab Vedotin (Padcev), for adults with advanced bladder cancer. Doctors want to see if it's safe, how well it works, and how the body handles it.